Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Kielce – page 2

187 clinical trials in Kielce, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Kielce at a glance
187
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

187 trials in Kielce

Open in trial search

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Coronary artery disease

Recruiting

Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Synektik S.A.

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Type 2 diabetes mellitus

Recruiting

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Recruiting

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Plasma cell myeloma

Recruiting

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Hypereosinophilic syndrome+1

Recruiting

Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Multiple sclerosis

Recruiting

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Kielce

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and lymphoma treatments. Studies evaluate novel drug combinations and targeted therapies for improved patient outcomes.

  • Blood cancers and solid tumors
  • Targeted therapy approaches
  • Combination treatment strategies

Advanced research includes studies on prostate cancer and neuroendocrine tumors using cutting-edge therapeutic approaches.

02 Neurological Disorders

Groundbreaking research in multiple sclerosis and Alzheimer's disease. Trials evaluate new treatments for both relapsing forms of MS and psychosis associated with Alzheimer's.

  • Disease-modifying therapies
  • Neurodegeneration treatments
  • Symptom management

Focus on developing innovative therapeutic solutions for complex neurological conditions.

03 Cardiovascular and Metabolic Studies

Comprehensive research addressing hypertension, cardiovascular disease, and metabolic disorders. Studies investigate preventive approaches and novel treatment combinations.

  • Heart failure prevention
  • Blood pressure management
  • Metabolic health

Innovative trials exploring new therapeutic strategies for cardiovascular risk reduction.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.